Kala soars as FDA accepts application to start eye defect drug trial
27/12/2022 22:05
** Shares of drugmaker Kala Pharmaceuticals KALA.O up
61.7% at $6.3 in aftermarket trade
** Co says the U.S. Food and Drug Administration has
accepted its application to start human trials for its lead
candidate, KPI-012, which is a potential treatment for
persistent non-healing corneal defect urn:newsml:reuters.com:*:nGNX9C5znQ
** Co on track to start second part of mid-stage trial in Q1
2023, with topline date expected in Q1 2024
** If the trial results are positive, Kala believes this
could serve as the first of two pivotal trials required to
support the submission of a marketing application to the FDA
** Up to last close, stock fell 93.5% YTD
(Reporting by Nandhini Srinivasan in Bengaluru)
((nandhini.srinivasan@thomsonreuters.com))